<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01612676</url>
  </required_header>
  <id_info>
    <org_study_id>000025</org_study_id>
    <secondary_id>2012-001254-26</secondary_id>
    <nct_id>NCT01612676</nct_id>
  </id_info>
  <brief_title>Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock</brief_title>
  <official_title>An Open Label Feasibility Trial Investigating FE 202158 as Potential Primary Vasopressor Treatment in Patients With Vasodilatory Hypotension in Early Septic Shock.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to investigate the potential of FE 202158 as a treatment which
      can stabilize blood pressure for treatment of patients in early septic shock.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Maintaining Target/Adequate Mean Arterial Pressure (MAP&gt;60 mmHg) Without Norepinephrine</measure>
    <time_frame>Day 1 up to Day 7 post-infusion (Data collected at Day 1 at 1, 2, 3, 4, 5, 6, 9, 12, 15, 18 and 24 h, Day 2 at 36 and 48 h, Day 3 at 72 h, Day 4 at 96 h, Day 5 at 120 h, Day 6 at 144 h, and Day 7 at 168 h). Data is presented for specific time points.</time_frame>
    <description>Mean arterial pressure (MAP) was measured intra-arterially on a continuous basis. Success percentage of patients maintaining target/adequate MAP (&gt;60 mmHg) without norepinephrine is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Dose of FE 202158</measure>
    <time_frame>Day 1 up to Day 7 post-infusion (Data collected at Day 1 at 1, 2, 3, 4, 5, 6, 9, 12, 15, 18 and 24 h, Day 2 at 36 and 48 h, Day 3 at 72 h, Day 4 at 96 h, Day 5 at 120 h, Day 6 at 144 h, and Day 7 at 168 h). Data is presented for specific time points.</time_frame>
    <description>Cumulative dose of FE 202158 was calculated from Day 1 up to Day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion Rate of FE 202158</measure>
    <time_frame>Day 1 up to Day 7 post-infusion (Data collected at Day 1 at 1, 2, 3, 4, 5, 6, 9, 12, 15, 18 and 24 h, Day 2 at 36 and 48 h, Day 3 at 72 h, Day 4 at 96 h, Day 5 at 120 h, Day 6 at 144 h, and Day 7 at 168 h). Data is presented for specific time points.</time_frame>
    <description>Infusion rate of FE 202158 was presented from Day 1 up to Day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Dose of Norepinephrine</measure>
    <time_frame>Day 1 up to Day 7 post-infusion (Data collected at Day 1 at 1, 2, 3, 4, 5, 6, 9, 12, 15, 18 and 24 h, Day 2 at 36 and 48 h, Day 3 at 72 h, Day 4 at 96 h, Day 5 at 120 h, Day 6 at 144 h, and Day 7 at 168 h). Data is presented for specific time points.</time_frame>
    <description>Norepinephrine was infused as required to maintain the target mean arterial pressure, if the highest infusion rate allowed of experimental drug FE 202158 did not provide adequate vasopressor support. Cumulative dose of norepinephrine was calculated from Day 1 up to Day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion Rate of Norepinephrine</measure>
    <time_frame>Day 1 up to Day 7 post-infusion (Data collected at Day 1 at 1, 2, 3, 4, 5, 6, 9, 12, 15, 18 and 24 h, Day 2 at 36 and 48 h, Day 3 at 72 h, Day 4 at 96 h, Day 5 at 120 h, Day 6 at 144 h, and Day 7 at 168 h). Data is presented for specific time points.</time_frame>
    <description>Norepinephrine was infused as required to maintain the target mean arterial pressure, if the highest infusion rate allowed of experimental drug FE 202158 did not provide adequate vasopressor support. Infusion rates and all changes in infusion rates of norepinephrine were recorded continuously during the 7 day maximum treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Septic Shock Resolution</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
    <description>The Kaplan-Meyer estimation of time to out of septic shock was estimated where time to (first) septic shock resolution was defined as time of end of infusion regimen. Intermittent off treatment periods were regarded as part of the shock duration.
Time to all but one patient out of septic shock is presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary Output</measure>
    <time_frame>Day 1 up to Day 7 post-infusion (Data collected on Day 1 at 24 h, Day 2 at 48 h, Day 3 at 72 h, Day 4 at 96 h, Day 5 at 120 h, Day 6 at 144 h, and Day 7 at 168 h). Data is presented for specific time points.</time_frame>
    <description>The urinary output was recorded every 24 hours up to Day 7, or as long as the patient was in intensive care unit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid Balance</measure>
    <time_frame>Day 1 up to Day 7 post-infusion (Data collected on Day 1 at 24 h, Day 2 at 48 h, Day 3 at 72 h, Day 4 at 96 h, Day 5 at 120 h, Day 6 at 144 h, and Day 7 at 168 h). Data is presented for specific time points.</time_frame>
    <description>The fluid balance (accumulated input/output) was recorded in 24-hour collecting periods when the patient was in the intensive care unit and during the infusion of FE 202158.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Investigator Reported Outcomes</measure>
    <time_frame>Day 1 up to Day 2</time_frame>
    <description>Investigator reported outcome on FE 202158 performance. Answers were graded on a visual analogue scale (VAS) from 0 to 10, 0 being the worst and 10 being the best outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity Assessment</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
    <description>Percentage of all the &quot;Days alive and out/free of&quot; intensive care unit, hospital, dialysis, or ventilation within Day 28 were summarized. Patients dying before or at Day 28 were counted as zero.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graded Morbidity</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
    <description>Collection of data on graded morbidity was performed on Day 28 in addition to the collection of data on time of stay in intensive care unit and hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
    <description>Collection of data on mortality was performed on Day 28 in addition to the collection of data on time of stay in intensive care unit and hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects on Lab Parameters, Vital Signs and Electrocardiogram</measure>
    <time_frame>Day 1 up to Day 7, and at follow-up assessments performed 24-72 hours after end of IMP infusion</time_frame>
    <description>Significant changes for vital signs (blood pressure, heart rate, mean arterial pressure), electrocardiogram (ECG), and laboratory parameters (clinical chemistry, haematology, haemostasis, and urinary parameters).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FE 202158</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FE 202158</intervention_name>
    <arm_group_label>Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form by the patient or a legal representative according to
             local regulations'

          -  Man or women 18 years of age or older

          -  Body weight below 115 kg for male patients and 100 kg for female patients

          -  Proven or suspected infection

          -  Septic shock, i.e. vasodilatory hypotension requiring vasopressor support

          -  Willing to use an adequate barrier method or hormonal method of contraception, if not
             abstinent, from informed consent to one week after the end of infusion of study
             medication

        Exclusion Criteria:

          -  Present or a history within the last 6 months of symptoms of acute coronary syndrome
             (myocardial infarction or unstable angina)

          -  Known or suspected endocarditis

          -  Hypovolaemia suspected on clinical grounds, e.g. cold extremities with delayed
             capillary filling, low cardiac filling pressure, marked systolic or pulse pressure
             variation or positive leg raising test

          -  Known or suspected cardiac failure

          -  Known or suspected infection with (HIV)-1, HIV-2, hepatitis B, or hepatitis C

          -  Pregnancy or breastfeeding

          -  Any cause of hypotension other than early septic shock

          -  Use of vasopressin or terlipressin within 7 days prior to start of IMP infusion

          -  Proven or suspected acute mesenteric ischemia, as judged by the investigator

          -  Known episode of septic shock within 1 month prior to screening

          -  Death anticipated within 24 hours, or due to the underlying disease within 3 months

          -  Known past or current 2nd and 3rd degree AV-block without a well functioning pacemaker

          -  Brain injury within current hospitalisation

          -  Present hospitalisation with burn injury

          -  Symptomatic peripheral vascular disease including Raynaud's syndrome

          -  Previously included in this trial

          -  Intake of an Investigational Medicinal Product (IMP) within the last 3 months (or
             longer if judged by the Investigator to possibly influence the outcome of the current
             study)

          -  Known participation in another interventional clinical trial

          -  Considered by the investigator to be unsuitable to participate in the trial for any
             other reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erasme Hospital Free University of Brussels</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Luc University Hospital</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Brussels</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2012</study_first_submitted>
  <study_first_submitted_qc>June 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2012</study_first_posted>
  <results_first_submitted>June 27, 2016</results_first_submitted>
  <results_first_submitted_qc>November 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 16, 2017</results_first_posted>
  <disposition_first_submitted>November 3, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>November 3, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 10, 2014</disposition_first_posted>
  <last_update_submitted>February 20, 2017</last_update_submitted>
  <last_update_submitted_qc>February 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The patients were recruited at the respective intensive care units at four centers (3 in Belgium and 1 in Denmark) between 05 Jul 2012 to 15 Nov 2013.</recruitment_details>
      <pre_assignment_details>Of the 159 patients screened, 31 patients were randomised and 30 patients were dosed. One patient in the 3.75 ng/kg/min dose group did not receive any study treatment due to an adverse event (elevation of troponin) recorded prior to infusion.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Infusion Regimen 1: 3.75 ng/kg/Min</title>
          <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
        </group>
        <group group_id="P2">
          <title>Infusion Regimen 2: 5.0 ng/kg/Min</title>
          <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 5.0 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
        </group>
        <group group_id="P3">
          <title>Infusion Regimen 3: 7.5 ng/kg/Min</title>
          <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min adjustable up to a maximum of 7.5 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
        </group>
        <group group_id="P4">
          <title>Infusion Regimen 4: Modified 3.75 ng/kg/Min</title>
          <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min, allowed to be increased to a maximum of 7.5 ng/kg/min if needed, with a maximum duration of 1 hour, during the first 6 hours of infusion. After 1 hour, or beyond the initial 6 hours, the infusion rate could not exceed 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Dosed</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed.</population>
      <group_list>
        <group group_id="B1">
          <title>Infusion Regimen 1</title>
          <description>FE 202158 0.1 mg/ml (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
        </group>
        <group group_id="B2">
          <title>Infusion Regimen 2</title>
          <description>FE 202158 0.1 mg/ml (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 5.0 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
        </group>
        <group group_id="B3">
          <title>Infusion Regimen 3</title>
          <description>FE 202158 0.1 mg/ml (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min adjustable up to a maximum of 7.5 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
        </group>
        <group group_id="B4">
          <title>Infusion Regimen 4</title>
          <description>FE 202158 0.1 mg/ml (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min, allowed to be increased to a maximum of 7.5 ng/kg/min if needed, with a maximum duration of 1 hour, during the first 6 hours of infusion. After 1 hour, or beyond the initial 6 hours, the infusion rate could not exceed 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="13"/>
            <count group_id="B5" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.0" spread="12.7"/>
                    <measurement group_id="B2" value="67.9" spread="13.7"/>
                    <measurement group_id="B3" value="64.8" spread="10.1"/>
                    <measurement group_id="B4" value="67.6" spread="13.2"/>
                    <measurement group_id="B5" value="67.4" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.6" spread="13.5"/>
                    <measurement group_id="B2" value="74.7" spread="17.7"/>
                    <measurement group_id="B3" value="81.3" spread="8.0"/>
                    <measurement group_id="B4" value="78.9" spread="15.3"/>
                    <measurement group_id="B5" value="76.3" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Sequential Organ Failure Assessment Score</title>
          <description>The Sequential Organ Failure Assessment score (SOFA) score is a scoring system to determine the extent of a person's organ function or rate of failure. The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems.
The total SOFA score is a sum of the individual scores and range from 4 to 24, 4 being the best and 24 being the worst patient status.</description>
          <units>Score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11" spread="3.32"/>
                    <measurement group_id="B2" value="10" spread="2.31"/>
                    <measurement group_id="B3" value="8.8" spread="3.19"/>
                    <measurement group_id="B4" value="9.31" spread="3.01"/>
                    <measurement group_id="B5" value="9.67" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Septic shock characteristic: Primary infection type</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bacterial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Septic shock characteristic: Primary infection location</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Abdominal cavity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary tract</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Maintaining Target/Adequate Mean Arterial Pressure (MAP&gt;60 mmHg) Without Norepinephrine</title>
        <description>Mean arterial pressure (MAP) was measured intra-arterially on a continuous basis. Success percentage of patients maintaining target/adequate MAP (&gt;60 mmHg) without norepinephrine is presented.</description>
        <time_frame>Day 1 up to Day 7 post-infusion (Data collected at Day 1 at 1, 2, 3, 4, 5, 6, 9, 12, 15, 18 and 24 h, Day 2 at 36 and 48 h, Day 3 at 72 h, Day 4 at 96 h, Day 5 at 120 h, Day 6 at 144 h, and Day 7 at 168 h). Data is presented for specific time points.</time_frame>
        <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed.</population>
        <group_list>
          <group group_id="O1">
            <title>Infusion Regimen 1: 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Infusion Regimen 2: 5.0 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 5.0 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Infusion Regimen 3: 7.5 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min adjustable up to a maximum of 7.5 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Infusion Regimen 4: Modified 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min, allowed to be increased to a maximum of 7.5 ng/kg/min if needed, with a maximum duration of 1 hour, during the first 6 hours of infusion. After 1 hour, or beyond the initial 6 hours, the infusion rate could not exceed 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Maintaining Target/Adequate Mean Arterial Pressure (MAP&gt;60 mmHg) Without Norepinephrine</title>
          <description>Mean arterial pressure (MAP) was measured intra-arterially on a continuous basis. Success percentage of patients maintaining target/adequate MAP (&gt;60 mmHg) without norepinephrine is presented.</description>
          <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <dispersion>60% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Post 1 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="4.4" upper_limit="49.0"/>
                    <measurement group_id="O2" value="42.9" lower_limit="22.8" upper_limit="65.0"/>
                    <measurement group_id="O3" value="60.0" lower_limit="32.7" upper_limit="83.1"/>
                    <measurement group_id="O4" value="7.7" lower_limit="1.7" upper_limit="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Post 3 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="4.4" upper_limit="49.0"/>
                    <measurement group_id="O2" value="14.3" lower_limit="3.1" upper_limit="37.1"/>
                    <measurement group_id="O3" value="60.0" lower_limit="32.7" upper_limit="83.1"/>
                    <measurement group_id="O4" value="53.8" lower_limit="38.7" upper_limit="68.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Post 6 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="5.4" upper_limit="58.2"/>
                    <measurement group_id="O2" value="14.3" lower_limit="3.1" upper_limit="37.1"/>
                    <measurement group_id="O3" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O4" value="76.9" lower_limit="61.6" upper_limit="88.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Post 12 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="32.7" upper_limit="83.1"/>
                    <measurement group_id="O2" value="28.6" lower_limit="12.0" upper_limit="51.7"/>
                    <measurement group_id="O3" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O4" value="53.8" lower_limit="38.7" upper_limit="68.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Post 18 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="32.7" upper_limit="83.1"/>
                    <measurement group_id="O2" value="42.9" lower_limit="22.8" upper_limit="65.0"/>
                    <measurement group_id="O3" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O4" value="66.7" lower_limit="50.3" upper_limit="80.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Post 24 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O2" value="42.9" lower_limit="22.8" upper_limit="65.0"/>
                    <measurement group_id="O3" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O4" value="61.5" lower_limit="46.1" upper_limit="75.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (Post 36 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O2" value="66.7" lower_limit="41.5" upper_limit="86.0"/>
                    <measurement group_id="O3" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O4" value="61.5" lower_limit="46.1" upper_limit="75.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (Post 48 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O2" value="50.0" lower_limit="26.9" upper_limit="73.1"/>
                    <measurement group_id="O3" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O4" value="76.9" lower_limit="61.6" upper_limit="88.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (Post 72 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O2" value="66.7" lower_limit="41.5" upper_limit="86.0"/>
                    <measurement group_id="O3" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O4" value="69.2" lower_limit="53.7" upper_limit="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (Post 96 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O2" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O3" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O4" value="76.9" lower_limit="61.6" upper_limit="88.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (Post 120 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O2" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O3" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O4" value="84.6" lower_limit="69.9" upper_limit="93.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 (Post 144 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O2" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O3" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O4" value="84.6" lower_limit="69.9" upper_limit="93.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (Post 168 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O2" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O3" value="80.0" lower_limit="51.0" upper_limit="95.6"/>
                    <measurement group_id="O4" value="76.9" lower_limit="61.6" upper_limit="88.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Output</title>
        <description>The urinary output was recorded every 24 hours up to Day 7, or as long as the patient was in intensive care unit.</description>
        <time_frame>Day 1 up to Day 7 post-infusion (Data collected on Day 1 at 24 h, Day 2 at 48 h, Day 3 at 72 h, Day 4 at 96 h, Day 5 at 120 h, Day 6 at 144 h, and Day 7 at 168 h). Data is presented for specific time points.</time_frame>
        <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed.</population>
        <group_list>
          <group group_id="O1">
            <title>Infusion Regimen 1: 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Infusion Regimen 2: 5.0 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 5.0 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Infusion Regimen 3: 7.5 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min adjustable up to a maximum of 7.5 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Infusion Regimen 4: Modified 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min, allowed to be increased to a maximum of 7.5 ng/kg/min if needed, with a maximum duration of 1 hour, during the first 6 hours of infusion. After 1 hour, or beyond the initial 6 hours, the infusion rate could not exceed 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Output</title>
          <description>The urinary output was recorded every 24 hours up to Day 7, or as long as the patient was in intensive care unit.</description>
          <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed.</population>
          <units>mL/kg</units>
          <param>Mean</param>
          <dispersion>60% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Post 24 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9" lower_limit="16.0" upper_limit="33.8"/>
                    <measurement group_id="O2" value="21.8" lower_limit="16.4" upper_limit="27.2"/>
                    <measurement group_id="O3" value="36.0" lower_limit="27.0" upper_limit="45.1"/>
                    <measurement group_id="O4" value="24.1" lower_limit="20.2" upper_limit="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (Post 48 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" lower_limit="26.7" upper_limit="59.1"/>
                    <measurement group_id="O2" value="31.0" lower_limit="23.9" upper_limit="38.0"/>
                    <measurement group_id="O3" value="55.9" lower_limit="41.8" upper_limit="69.9"/>
                    <measurement group_id="O4" value="48.1" lower_limit="36.6" upper_limit="59.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (Post 72 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3" lower_limit="32.3" upper_limit="82.3"/>
                    <measurement group_id="O2" value="43.2" lower_limit="32.3" upper_limit="54.1"/>
                    <measurement group_id="O3" value="79.2" lower_limit="58.0" upper_limit="100.4"/>
                    <measurement group_id="O4" value="72.3" lower_limit="53.7" upper_limit="91.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (Post 96 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" lower_limit="37.6" upper_limit="98.4"/>
                    <measurement group_id="O2" value="58.8" lower_limit="42.1" upper_limit="75.4"/>
                    <measurement group_id="O3" value="100.5" lower_limit="74.4" upper_limit="126.7"/>
                    <measurement group_id="O4" value="94.0" lower_limit="69.4" upper_limit="118.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (Post 120 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.3" lower_limit="42.3" upper_limit="106.3"/>
                    <measurement group_id="O2" value="73.3" lower_limit="51.1" upper_limit="95.6"/>
                    <measurement group_id="O3" value="125.2" lower_limit="94.3" upper_limit="156.1"/>
                    <measurement group_id="O4" value="106.2" lower_limit="79.2" upper_limit="133.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 (Post 144 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" lower_limit="46.6" upper_limit="116.9"/>
                    <measurement group_id="O2" value="85.9" lower_limit="58.2" upper_limit="113.5"/>
                    <measurement group_id="O3" value="139.8" lower_limit="104.7" upper_limit="175.0"/>
                    <measurement group_id="O4" value="111.9" lower_limit="84.8" upper_limit="139.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (Post 168 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.0" lower_limit="46.8" upper_limit="117.2"/>
                    <measurement group_id="O2" value="96.1" lower_limit="64.2" upper_limit="128.0"/>
                    <measurement group_id="O3" value="144.7" lower_limit="108.2" upper_limit="181.2"/>
                    <measurement group_id="O4" value="115.1" lower_limit="87.7" upper_limit="142.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fluid Balance</title>
        <description>The fluid balance (accumulated input/output) was recorded in 24-hour collecting periods when the patient was in the intensive care unit and during the infusion of FE 202158.</description>
        <time_frame>Day 1 up to Day 7 post-infusion (Data collected on Day 1 at 24 h, Day 2 at 48 h, Day 3 at 72 h, Day 4 at 96 h, Day 5 at 120 h, Day 6 at 144 h, and Day 7 at 168 h). Data is presented for specific time points.</time_frame>
        <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed.</population>
        <group_list>
          <group group_id="O1">
            <title>Infusion Regimen 1: 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Infusion Regimen 2: 5.0 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 5.0 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Infusion Regimen 3: 7.5 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min adjustable up to a maximum of 7.5 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Infusion Regimen 4: Modified 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min, allowed to be increased to a maximum of 7.5 ng/kg/min if needed, with a maximum duration of 1 hour, during the first 6 hours of infusion. After 1 hour, or beyond the initial 6 hours, the infusion rate could not exceed 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Fluid Balance</title>
          <description>The fluid balance (accumulated input/output) was recorded in 24-hour collecting periods when the patient was in the intensive care unit and during the infusion of FE 202158.</description>
          <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed.</population>
          <units>mL/kg</units>
          <param>Mean</param>
          <dispersion>60% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Post 24 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="23" upper_limit="77"/>
                    <measurement group_id="O2" value="72" lower_limit="60" upper_limit="85"/>
                    <measurement group_id="O3" value="62" lower_limit="50" upper_limit="74"/>
                    <measurement group_id="O4" value="61" lower_limit="52" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (Post 48 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="34" upper_limit="103"/>
                    <measurement group_id="O2" value="128" lower_limit="103" upper_limit="153"/>
                    <measurement group_id="O3" value="96" lower_limit="78" upper_limit="113"/>
                    <measurement group_id="O4" value="75" lower_limit="66" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (Post 72 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="32" upper_limit="118"/>
                    <measurement group_id="O2" value="173" lower_limit="141" upper_limit="206"/>
                    <measurement group_id="O3" value="115" lower_limit="94" upper_limit="135"/>
                    <measurement group_id="O4" value="72" lower_limit="61" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (Post 96 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="30" upper_limit="122"/>
                    <measurement group_id="O2" value="189" lower_limit="153" upper_limit="226"/>
                    <measurement group_id="O3" value="107" lower_limit="90" upper_limit="124"/>
                    <measurement group_id="O4" value="68" lower_limit="57" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (Post 120 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="31" upper_limit="130"/>
                    <measurement group_id="O2" value="209" lower_limit="172" upper_limit="247"/>
                    <measurement group_id="O3" value="90" lower_limit="78" upper_limit="102"/>
                    <measurement group_id="O4" value="69" lower_limit="57" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 (Post 144 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="31" upper_limit="138"/>
                    <measurement group_id="O2" value="209" lower_limit="166" upper_limit="252"/>
                    <measurement group_id="O3" value="88" lower_limit="75" upper_limit="100"/>
                    <measurement group_id="O4" value="76" lower_limit="61" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (Post 168 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="33" upper_limit="147"/>
                    <measurement group_id="O2" value="220" lower_limit="174" upper_limit="267"/>
                    <measurement group_id="O3" value="98" lower_limit="77" upper_limit="119"/>
                    <measurement group_id="O4" value="78" lower_limit="62" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Investigator Reported Outcomes</title>
        <description>Investigator reported outcome on FE 202158 performance. Answers were graded on a visual analogue scale (VAS) from 0 to 10, 0 being the worst and 10 being the best outcome.</description>
        <time_frame>Day 1 up to Day 2</time_frame>
        <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed.</population>
        <group_list>
          <group group_id="O1">
            <title>Infusion Regimen 1: 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Infusion Regimen 2: 5.0 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 5.0 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Infusion Regimen 3: 7.5 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min adjustable up to a maximum of 7.5 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Infusion Regimen 4: Modified 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min, allowed to be increased to a maximum of 7.5 ng/kg/min if needed, with a maximum duration of 1 hour, during the first 6 hours of infusion. After 1 hour, or beyond the initial 6 hours, the infusion rate could not exceed 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Investigator Reported Outcomes</title>
          <description>Investigator reported outcome on FE 202158 performance. Answers were graded on a visual analogue scale (VAS) from 0 to 10, 0 being the worst and 10 being the best outcome.</description>
          <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed.</population>
          <units>Score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Onset of action adequate to reach target MAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="3.78"/>
                    <measurement group_id="O2" value="3.57" spread="2.51"/>
                    <measurement group_id="O3" value="9.0" spread="1.22"/>
                    <measurement group_id="O4" value="7.85" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAP maintained within desired boundaries (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="2.77"/>
                    <measurement group_id="O2" value="3.86" spread="2.67"/>
                    <measurement group_id="O3" value="9" spread="1.22"/>
                    <measurement group_id="O4" value="7.69" spread="3.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAP maintained within desired boundaries (Day 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="0"/>
                    <measurement group_id="O2" value="4" spread="2.35"/>
                    <measurement group_id="O3" value="8.75" spread="1.26"/>
                    <measurement group_id="O4" value="6.71" spread="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confidence to use FE 202158 as primary treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="1.91"/>
                    <measurement group_id="O2" value="5.5" spread="2.43"/>
                    <measurement group_id="O3" value="9.5" spread="0.577"/>
                    <measurement group_id="O4" value="8.18" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morbidity Assessment</title>
        <description>Percentage of all the Days alive and out/free of intensive care unit, hospital, dialysis, or ventilation within Day 28 were summarized. Patients dying before or at Day 28 were counted as zero.</description>
        <time_frame>Day 1 up to Day 28</time_frame>
        <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed.</population>
        <group_list>
          <group group_id="O1">
            <title>Infusion Regimen 1: 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Infusion Regimen 2: 5.0 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 5.0 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Infusion Regimen 3: 7.5 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min adjustable up to a maximum of 7.5 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Infusion Regimen 4: Modified 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min, allowed to be increased to a maximum of 7.5 ng/kg/min if needed, with a maximum duration of 1 hour, during the first 6 hours of infusion. After 1 hour, or beyond the initial 6 hours, the infusion rate could not exceed 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Morbidity Assessment</title>
          <description>Percentage of all the Days alive and out/free of intensive care unit, hospital, dialysis, or ventilation within Day 28 were summarized. Patients dying before or at Day 28 were counted as zero.</description>
          <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed.</population>
          <units>percentage of days within 28 days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days alive and out of intensive care unit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.6"/>
                    <measurement group_id="O2" value="31.4"/>
                    <measurement group_id="O3" value="61.2"/>
                    <measurement group_id="O4" value="58.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days alive and out of hospital</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                    <measurement group_id="O2" value="3.6"/>
                    <measurement group_id="O3" value="17.8"/>
                    <measurement group_id="O4" value="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days alive and free of dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="38.6"/>
                    <measurement group_id="O3" value="80"/>
                    <measurement group_id="O4" value="76.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days alive and free of ventilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.8"/>
                    <measurement group_id="O2" value="39.6"/>
                    <measurement group_id="O3" value="75.6"/>
                    <measurement group_id="O4" value="73.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graded Morbidity</title>
        <description>Collection of data on graded morbidity was performed on Day 28 in addition to the collection of data on time of stay in intensive care unit and hospital.</description>
        <time_frame>Day 1 up to Day 28</time_frame>
        <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed.</population>
        <group_list>
          <group group_id="O1">
            <title>Infusion Regimen 1: 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Infusion Regimen 2: 5.0 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 5.0 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Infusion Regimen 3: 7.5 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min adjustable up to a maximum of 7.5 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Infusion Regimen 4: Modified 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min, allowed to be increased to a maximum of 7.5 ng/kg/min if needed, with a maximum duration of 1 hour, during the first 6 hours of infusion. After 1 hour, or beyond the initial 6 hours, the infusion rate could not exceed 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Graded Morbidity</title>
          <description>Collection of data on graded morbidity was performed on Day 28 in addition to the collection of data on time of stay in intensive care unit and hospital.</description>
          <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alive and out of hospital</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>In hospital (not intensive care unit)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>In intensive care unit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dead</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Dose of FE 202158</title>
        <description>Cumulative dose of FE 202158 was calculated from Day 1 up to Day 7.</description>
        <time_frame>Day 1 up to Day 7 post-infusion (Data collected at Day 1 at 1, 2, 3, 4, 5, 6, 9, 12, 15, 18 and 24 h, Day 2 at 36 and 48 h, Day 3 at 72 h, Day 4 at 96 h, Day 5 at 120 h, Day 6 at 144 h, and Day 7 at 168 h). Data is presented for specific time points.</time_frame>
        <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed.</population>
        <group_list>
          <group group_id="O1">
            <title>Infusion Regimen 1: 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Infusion Regimen 2: 5.0 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 5.0 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Infusion Regimen 3: 7.5 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min adjustable up to a maximum of 7.5 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Infusion Regimen 4: Modified 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min, allowed to be increased to a maximum of 7.5 ng/kg/min if needed, with a maximum duration of 1 hour, during the first 6 hours of infusion. After 1 hour, or beyond the initial 6 hours, the infusion rate could not exceed 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Dose of FE 202158</title>
          <description>Cumulative dose of FE 202158 was calculated from Day 1 up to Day 7.</description>
          <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed.</population>
          <units>ng/kg</units>
          <param>Mean</param>
          <dispersion>60% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Post 12 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2451" lower_limit="2226.3" upper_limit="2675.8"/>
                    <measurement group_id="O2" value="3276.3" lower_limit="2941.3" upper_limit="3611.3"/>
                    <measurement group_id="O3" value="2946" lower_limit="2426.2" upper_limit="3465.8"/>
                    <measurement group_id="O4" value="2377" lower_limit="2220.2" upper_limit="2533.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Post 24 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4217.4" lower_limit="3736.5" upper_limit="4698.3"/>
                    <measurement group_id="O2" value="5502.2" lower_limit="4698.7" upper_limit="6305.7"/>
                    <measurement group_id="O3" value="4927.3" lower_limit="4064.8" upper_limit="5789.8"/>
                    <measurement group_id="O4" value="3818.8" lower_limit="3429.6" upper_limit="4208.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (Post 36 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4463.9" lower_limit="3877.0" upper_limit="5050.7"/>
                    <measurement group_id="O2" value="7535.9" lower_limit="6206.2" upper_limit="8865.7"/>
                    <measurement group_id="O3" value="5842" lower_limit="4554.6" upper_limit="7129.4"/>
                    <measurement group_id="O4" value="4619.2" lower_limit="4005.0" upper_limit="5233.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (Post 48 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4523.9" lower_limit="3900.8" upper_limit="5146.9"/>
                    <measurement group_id="O2" value="9185" lower_limit="7405.2" upper_limit="10963.9"/>
                    <measurement group_id="O3" value="6716" lower_limit="4674.3" upper_limit="8757.6"/>
                    <measurement group_id="O4" value="5225" lower_limit="4401.7" upper_limit="6048.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (Post 72 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4523.9" lower_limit="3900.8" upper_limit="5146.9"/>
                    <measurement group_id="O2" value="11511.4" lower_limit="9096.1" upper_limit="13926.7"/>
                    <measurement group_id="O3" value="7902" lower_limit="4758.8" upper_limit="11045.1"/>
                    <measurement group_id="O4" value="5860.1" lower_limit="4763.9" upper_limit="6956.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (Post 96 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4523.9" lower_limit="3900.8" upper_limit="5146.9"/>
                    <measurement group_id="O2" value="12204.6" lower_limit="9365.7" upper_limit="15043.4"/>
                    <measurement group_id="O3" value="7999.8" lower_limit="4765.3" upper_limit="11234.3"/>
                    <measurement group_id="O4" value="6298.6" lower_limit="4939.5" upper_limit="7657.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (Post 120 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4523.9" lower_limit="3900.8" upper_limit="5146.9"/>
                    <measurement group_id="O2" value="12865.3" lower_limit="9561.7" upper_limit="16168.9"/>
                    <measurement group_id="O3" value="7999.8" lower_limit="4765.3" upper_limit="11234.3"/>
                    <measurement group_id="O4" value="6621.8" lower_limit="5033.5" upper_limit="8210.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 (Post 144 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4523.9" lower_limit="3900.8" upper_limit="5146.9"/>
                    <measurement group_id="O2" value="13543.7" lower_limit="9724.0" upper_limit="17363.3"/>
                    <measurement group_id="O3" value="7999.8" lower_limit="4765.3" upper_limit="11234.3"/>
                    <measurement group_id="O4" value="6696.5" lower_limit="5052.9" upper_limit="8340.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (Post 168 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4523.9" lower_limit="3900.8" upper_limit="5146.9"/>
                    <measurement group_id="O2" value="13543.7" lower_limit="9724.0" upper_limit="17363.3"/>
                    <measurement group_id="O3" value="7999.8" lower_limit="4765.3" upper_limit="11234.3"/>
                    <measurement group_id="O4" value="7003.7" lower_limit="5126.0" upper_limit="8881.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Infusion Rate of FE 202158</title>
        <description>Infusion rate of FE 202158 was presented from Day 1 up to Day 7.</description>
        <time_frame>Day 1 up to Day 7 post-infusion (Data collected at Day 1 at 1, 2, 3, 4, 5, 6, 9, 12, 15, 18 and 24 h, Day 2 at 36 and 48 h, Day 3 at 72 h, Day 4 at 96 h, Day 5 at 120 h, Day 6 at 144 h, and Day 7 at 168 h). Data is presented for specific time points.</time_frame>
        <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed.</population>
        <group_list>
          <group group_id="O1">
            <title>Infusion Regimen 1: 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Infusion Regimen 2: 5.0 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 5.0 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Infusion Regimen 3: 7.5 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min adjustable up to a maximum of 7.5 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Infusion Regimen 4: Modified 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min, allowed to be increased to a maximum of 7.5 ng/kg/min if needed, with a maximum duration of 1 hour, during the first 6 hours of infusion. After 1 hour, or beyond the initial 6 hours, the infusion rate could not exceed 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Infusion Rate of FE 202158</title>
          <description>Infusion rate of FE 202158 was presented from Day 1 up to Day 7.</description>
          <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed.</population>
          <units>ng/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Post 12 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.25" spread="1.29"/>
                    <measurement group_id="O2" value="4.13" spread="2.09"/>
                    <measurement group_id="O3" value="3.08" spread="2.56"/>
                    <measurement group_id="O4" value="2.43" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Post 24 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="1.88"/>
                    <measurement group_id="O2" value="3.39" spread="2.37"/>
                    <measurement group_id="O3" value="1.59" spread="2.19"/>
                    <measurement group_id="O4" value="1.39" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (Post 36 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.47"/>
                    <measurement group_id="O2" value="2.66" spread="2.27"/>
                    <measurement group_id="O3" value="2.08" spread="2.77"/>
                    <measurement group_id="O4" value="1.25" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (Post 48 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="2.51" spread="2.29"/>
                    <measurement group_id="O3" value="1.79" spread="3.57"/>
                    <measurement group_id="O4" value="0.69" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (Post 72 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.82" spread="2.02"/>
                    <measurement group_id="O3" value="0.61" spread="1.22"/>
                    <measurement group_id="O4" value="0.39" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (Post 96 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.33" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (Post 120 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.99" spread="2.21"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 (Post 144 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (Post 168 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.33" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Dose of Norepinephrine</title>
        <description>Norepinephrine was infused as required to maintain the target mean arterial pressure, if the highest infusion rate allowed of experimental drug FE 202158 did not provide adequate vasopressor support. Cumulative dose of norepinephrine was calculated from Day 1 up to Day 7.</description>
        <time_frame>Day 1 up to Day 7 post-infusion (Data collected at Day 1 at 1, 2, 3, 4, 5, 6, 9, 12, 15, 18 and 24 h, Day 2 at 36 and 48 h, Day 3 at 72 h, Day 4 at 96 h, Day 5 at 120 h, Day 6 at 144 h, and Day 7 at 168 h). Data is presented for specific time points.</time_frame>
        <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed. One patient in the 7.5 ng/kg/min group started the vasopressor support without prior administration of norepinephrine, and MAP was adequately controlled as needed.</population>
        <group_list>
          <group group_id="O1">
            <title>Infusion Regimen 1: 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Infusion Regimen 2: 5.0 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 5.0 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Infusion Regimen 3: 7.5 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min adjustable up to a maximum of 7.5 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Infusion Regimen 4: Modified 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min, allowed to be increased to a maximum of 7.5 ng/kg/min if needed, with a maximum duration of 1 hour, during the first 6 hours of infusion. After 1 hour, or beyond the initial 6 hours, the infusion rate could not exceed 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Dose of Norepinephrine</title>
          <description>Norepinephrine was infused as required to maintain the target mean arterial pressure, if the highest infusion rate allowed of experimental drug FE 202158 did not provide adequate vasopressor support. Cumulative dose of norepinephrine was calculated from Day 1 up to Day 7.</description>
          <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed. One patient in the 7.5 ng/kg/min group started the vasopressor support without prior administration of norepinephrine, and MAP was adequately controlled as needed.</population>
          <units>g/kg</units>
          <param>Mean</param>
          <dispersion>60% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Post 12 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="358.1" lower_limit="91.8" upper_limit="624.3"/>
                    <measurement group_id="O2" value="172.1" lower_limit="96.5" upper_limit="247.8"/>
                    <measurement group_id="O3" value="118.0" lower_limit="12.7" upper_limit="223.3"/>
                    <measurement group_id="O4" value="73.1" lower_limit="47.2" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Post 24 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="720.8" lower_limit="131.8" upper_limit="1309.7"/>
                    <measurement group_id="O2" value="338.0" lower_limit="171.5" upper_limit="504.6"/>
                    <measurement group_id="O3" value="357.5" lower_limit="17.8" upper_limit="697.2"/>
                    <measurement group_id="O4" value="149.5" lower_limit="90.4" upper_limit="208.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (Post 36 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="720.8" lower_limit="131.8" upper_limit="1309.7"/>
                    <measurement group_id="O2" value="406.2" lower_limit="214.7" upper_limit="597.6"/>
                    <measurement group_id="O3" value="778.2" lower_limit="26.9" upper_limit="1529.5"/>
                    <measurement group_id="O4" value="197.8" lower_limit="111.4" upper_limit="284.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (Post 48 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="720.8" lower_limit="131.8" upper_limit="1309.7"/>
                    <measurement group_id="O2" value="495.5" lower_limit="296.4" upper_limit="694.5"/>
                    <measurement group_id="O3" value="778.4" lower_limit="27.2" upper_limit="1529.7"/>
                    <measurement group_id="O4" value="232.8" lower_limit="120.6" upper_limit="345.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (Post 72 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="720.8" lower_limit="131.8" upper_limit="1309.7"/>
                    <measurement group_id="O2" value="669.0" lower_limit="390.8" upper_limit="947.2"/>
                    <measurement group_id="O3" value="778.4" lower_limit="27.2" upper_limit="1529.7"/>
                    <measurement group_id="O4" value="279.1" lower_limit="129.5" upper_limit="428.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (Post 96 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="720.8" lower_limit="131.8" upper_limit="1309.7"/>
                    <measurement group_id="O2" value="829.6" lower_limit="438.1" upper_limit="1221.1"/>
                    <measurement group_id="O3" value="778.4" lower_limit="27.2" upper_limit="1529.7"/>
                    <measurement group_id="O4" value="303.1" lower_limit="133.6" upper_limit="472.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (Post 120 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="720.8" lower_limit="131.8" upper_limit="1309.7"/>
                    <measurement group_id="O2" value="1039.5" lower_limit="473.7" upper_limit="1605.2"/>
                    <measurement group_id="O3" value="778.4" lower_limit="27.2" upper_limit="1529.7"/>
                    <measurement group_id="O4" value="307.8" lower_limit="134.4" upper_limit="481.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 (Post 144 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="720.8" lower_limit="131.8" upper_limit="1309.7"/>
                    <measurement group_id="O2" value="1152.0" lower_limit="489.2" upper_limit="1814.7"/>
                    <measurement group_id="O3" value="778.4" lower_limit="27.2" upper_limit="1529.7"/>
                    <measurement group_id="O4" value="307.8" lower_limit="134.4" upper_limit="481.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (Post 168 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="720.8" lower_limit="131.8" upper_limit="1309.7"/>
                    <measurement group_id="O2" value="1152.0" lower_limit="489.2" upper_limit="1814.7"/>
                    <measurement group_id="O3" value="778.4" lower_limit="27.2" upper_limit="1529.7"/>
                    <measurement group_id="O4" value="311.1" lower_limit="134.9" upper_limit="487.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Infusion Rate of Norepinephrine</title>
        <description>Norepinephrine was infused as required to maintain the target mean arterial pressure, if the highest infusion rate allowed of experimental drug FE 202158 did not provide adequate vasopressor support. Infusion rates and all changes in infusion rates of norepinephrine were recorded continuously during the 7 day maximum treatment period.</description>
        <time_frame>Day 1 up to Day 7 post-infusion (Data collected at Day 1 at 1, 2, 3, 4, 5, 6, 9, 12, 15, 18 and 24 h, Day 2 at 36 and 48 h, Day 3 at 72 h, Day 4 at 96 h, Day 5 at 120 h, Day 6 at 144 h, and Day 7 at 168 h). Data is presented for specific time points.</time_frame>
        <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed. One patient in the 7.5 ng/kg/min group started the vasopressor support without prior administration of norepinephrine, and MAP was adequately controlled as needed.</population>
        <group_list>
          <group group_id="O1">
            <title>Infusion Regimen 1: 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Infusion Regimen 2: 5.0 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 5.0 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Infusion Regimen 3: 7.5 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min adjustable up to a maximum of 7.5 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Infusion Regimen 4: Modified 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min, allowed to be increased to a maximum of 7.5 ng/kg/min if needed, with a maximum duration of 1 hour, during the first 6 hours of infusion. After 1 hour, or beyond the initial 6 hours, the infusion rate could not exceed 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Infusion Rate of Norepinephrine</title>
          <description>Norepinephrine was infused as required to maintain the target mean arterial pressure, if the highest infusion rate allowed of experimental drug FE 202158 did not provide adequate vasopressor support. Infusion rates and all changes in infusion rates of norepinephrine were recorded continuously during the 7 day maximum treatment period.</description>
          <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed. One patient in the 7.5 ng/kg/min group started the vasopressor support without prior administration of norepinephrine, and MAP was adequately controlled as needed.</population>
          <units>g/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Post 12 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.341" spread="0.691"/>
                    <measurement group_id="O2" value="0.281" spread="0.444"/>
                    <measurement group_id="O3" value="0.215" spread="0.405"/>
                    <measurement group_id="O4" value="0.111" spread="0.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Post 24 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" spread="0.020"/>
                    <measurement group_id="O2" value="0.222" spread="0.402"/>
                    <measurement group_id="O3" value="0.639" spread="1.280"/>
                    <measurement group_id="O4" value="0.089" spread="0.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (Post 36 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.000"/>
                    <measurement group_id="O2" value="0.049" spread="0.101"/>
                    <measurement group_id="O3" value="0.000" spread="0.000"/>
                    <measurement group_id="O4" value="0.061" spread="0.171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (Post 48 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.000"/>
                    <measurement group_id="O2" value="0.105" spread="0.215"/>
                    <measurement group_id="O3" value="0.004" spread="0.008"/>
                    <measurement group_id="O4" value="0.057" spread="0.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (Post 72 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.000"/>
                    <measurement group_id="O2" value="0.120" spread="0.270"/>
                    <measurement group_id="O3" value="0.000" spread="0.000"/>
                    <measurement group_id="O4" value="0.024" spread="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (Post 96 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.000"/>
                    <measurement group_id="O2" value="0.184" spread="0.411"/>
                    <measurement group_id="O3" value="0.000" spread="0.000"/>
                    <measurement group_id="O4" value="0.005" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (Post 120 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.000"/>
                    <measurement group_id="O2" value="0.172" spread="0.385"/>
                    <measurement group_id="O3" value="0.000" spread="0.000"/>
                    <measurement group_id="O4" value="0.000" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 (144 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.000"/>
                    <measurement group_id="O2" value="0.000" spread="0.000"/>
                    <measurement group_id="O3" value="0.000" spread="0.000"/>
                    <measurement group_id="O4" value="0.000" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (Post 168 h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.000"/>
                    <measurement group_id="O2" value="0.000" spread="0.000"/>
                    <measurement group_id="O3" value="0.000" spread="0.000"/>
                    <measurement group_id="O4" value="0.006" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Septic Shock Resolution</title>
        <description>The Kaplan-Meyer estimation of time to out of septic shock was estimated where time to (first) septic shock resolution was defined as time of end of infusion regimen. Intermittent off treatment periods were regarded as part of the shock duration.
Time to all but one patient out of septic shock is presented.</description>
        <time_frame>Day 1 up to Day 28</time_frame>
        <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed.</population>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>The full analysis data set (FAS) comprised data from all dosed patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Septic Shock Resolution</title>
          <description>The Kaplan-Meyer estimation of time to out of septic shock was estimated where time to (first) septic shock resolution was defined as time of end of infusion regimen. Intermittent off treatment periods were regarded as part of the shock duration.
Time to all but one patient out of septic shock is presented.</description>
          <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed.</population>
          <units>Hours</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3.75 ng/kg/min (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5.0 ng/kg/min (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7.5 ng/kg/min (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Modified 3.75 ng/kg/min (n=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>Collection of data on mortality was performed on Day 28 in addition to the collection of data on time of stay in intensive care unit and hospital.</description>
        <time_frame>Day 1 up to Day 28</time_frame>
        <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed.</population>
        <group_list>
          <group group_id="O1">
            <title>Infusion Regimen 1: 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Infusion Regimen 2: 5.0 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 5.0 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Infusion Regimen 3: 7.5 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min adjustable up to a maximum of 7.5 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Infusion Regimen 4: Modified 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min, allowed to be increased to a maximum of 7.5 ng/kg/min if needed, with a maximum duration of 1 hour, during the first 6 hours of infusion. After 1 hour, or beyond the initial 6 hours, the infusion rate could not exceed 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>Collection of data on mortality was performed on Day 28 in addition to the collection of data on time of stay in intensive care unit and hospital.</description>
          <population>Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dead</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Effects on Lab Parameters, Vital Signs and Electrocardiogram</title>
        <description>Significant changes for vital signs (blood pressure, heart rate, mean arterial pressure), electrocardiogram (ECG), and laboratory parameters (clinical chemistry, haematology, haemostasis, and urinary parameters).</description>
        <time_frame>Day 1 up to Day 7, and at follow-up assessments performed 24-72 hours after end of IMP infusion</time_frame>
        <population>The safety analysis set comprised of all allocated and dosed patients and were analyzed according to the actual dosing regimen received.</population>
        <group_list>
          <group group_id="O1">
            <title>Infusion Regimen 1: 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Infusion Regimen 2: 5.0 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 5.0 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Infusion Regimen 3: 7.5 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min adjustable up to a maximum of 7.5 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Infusion Regimen 4: Modified 3.75 ng/kg/Min</title>
            <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min, allowed to be increased to a maximum of 7.5 ng/kg/min if needed, with a maximum duration of 1 hour, during the first 6 hours of infusion. After 1 hour, or beyond the initial 6 hours, the infusion rate could not exceed 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Effects on Lab Parameters, Vital Signs and Electrocardiogram</title>
          <description>Significant changes for vital signs (blood pressure, heart rate, mean arterial pressure), electrocardiogram (ECG), and laboratory parameters (clinical chemistry, haematology, haemostasis, and urinary parameters).</description>
          <population>The safety analysis set comprised of all allocated and dosed patients and were analyzed according to the actual dosing regimen received.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with adverse effects on lab parameters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with adverse effects on vital signs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with adverse effects on electrocardiogram</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded from start of study up to the end of trial on Day 28, or end of follow-up period as applicable.</time_frame>
      <desc>Collection of adverse events comprised the patient's positive response to questions about their health, symptoms spontaneously reported by the patient, and clinically relevant changes and abnormalities observed by the investigator.</desc>
      <group_list>
        <group group_id="E1">
          <title>Infusion Regimen 1: 3.75 ng/kg/Min</title>
          <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
        </group>
        <group group_id="E2">
          <title>Infusion Regimen 2: 5.0 ng/kg/Min</title>
          <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5 ng/kg/min, adjustable up to 5.0 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
        </group>
        <group group_id="E3">
          <title>Infusion Regimen 3: 7.5 ng/kg/Min</title>
          <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min adjustable up to a maximum of 7.5 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
        </group>
        <group group_id="E4">
          <title>Infusion Regimen 4: Modified 3.75 ng/kg/Min</title>
          <description>FE 202158 0.1 mg/mL (10 mM acetate buffer, pH 4) was administered at initial infusion rate of 2.5-3.75 ng/kg/min, allowed to be increased to a maximum of 7.5 ng/kg/min if needed, with a maximum duration of 1 hour, during the first 6 hours of infusion. After 1 hour, or beyond the initial 6 hours, the infusion rate could not exceed 3.75 ng/kg/min. Each patient received FE 202158 until recovered from the shock, however for not more than 7 days.</description>
        </group>
        <group group_id="E5">
          <title>Total</title>
          <description>Summation of adverse events in all treatment arms</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Intestinal ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Colostomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Distributive shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Peripheral ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Myocardial depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Abdominal compartment syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Oesophageal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cytolytic hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hepatic congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Metabolic alkalosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypoventilation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Laryngospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were no limitations or caveats in this trial</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Development Support</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

